CD274 and cancer: In parallel, when antibodies against PD-L1 are used, it is possible that they are unable to efficiently block the two different arms of PD-L1-mediated activities simultaneously: PD-L1-induced immune suppression and pro-metastatic intrinsic activities in the cancer cells.